SCHEMBL4423583

SCHEMBL4423583

O=C(Nc1ccc(N2CCOCC2)c(F)c1)C1C2CN(S(=O)(=O)c3ccc4ccccc4c3)CC21

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
HPGD P15428 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KMT2A Q03164 9/20 0.49
MEN1 O00255 8/20 0.49
MAPT P10636 6/20 0.49
LMNA P02545 4/20 0.49
HTT P42858 4/20 0.49
GAA P10253 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
PKM P14618 1/20 0.45
TSHR P16473 1/20 0.45
ALOX12 P18054 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4425056 0.88 KMT2A (0.48) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4414156 0.88 SMN1; SMN2 (0.52) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4417870 0.87 ALDH1A1 (0.53) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4413581 0.86 RAB9A (0.53) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4417779 0.86 KMT2A (0.49) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4414453 0.85 EPHX2 (0.54) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4421514 0.85 MAPT (0.47) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4415023 0.84 SLC6A9 (0.48) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4423587 0.83 MEN1 (0.46) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4415659 0.83 HTT (0.43) ALDH1A1HPGDNPSR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 ALDH1A1 3166/4885HPGD 2537/4885NPSR1 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.